Rubicon Research Limited (BOM:544578)

India flag India · Delayed Price · Currency is INR
769.10
-11.95 (-1.53%)
At close: Mar 2, 2026
Market Cap 127.42B
Revenue (ttm) 15.98B
Net Income (ttm) 2.06B
Shares Out n/a
EPS (ttm) 13.03
PE Ratio 61.79
Forward PE 42.15
Dividend n/a
Ex-Dividend Date n/a
Volume 23,704
Average Volume 20,887
Open 730.00
Previous Close 781.05
Day's Range 730.00 - 788.05
52-Week Range 571.00 - 887.95
Beta n/a
RSI 55.69
Earnings Date Feb 3, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ... [Read more]

Industry Pharmaceutical Preparations
Founded 1999
Employees 903
Stock Exchange Bombay Stock Exchange
Ticker Symbol 544578
Full Company Profile

Financial Performance

In fiscal year 2025, Rubicon Research's revenue was 12.84 billion, an increase of 50.40% compared to the previous year's 8.54 billion. Earnings were 1.34 billion, an increase of 47.63%.

Financial Statements

News

There is no news available yet.